Pharmacology
Summary
Insomnia, particularly prevalent among the elderly, can significantly affect quality of life. While non-pharmacologic interventions like CBT and sleep hygiene serve as foundational management strategies, pharmacotherapy can be used to offer short-term relief. Prominent among these are the non-benzodiazepine hypnotics: zolpidem, zaleplon, and eszopiclone. Structurally related to benzodiazepines, these drugs elicit their sedative effects by binding to the GABA-A receptor, inducing neuronal hyperpolarization, which in turn inhibits synaptic transmissions throughout the central nervous system.
The specificity of non-benzodiazepine hypnotics, such as zolpidem, for certain subunits of the GABA-A receptor results in less anticonvulsant and anxiolytic activity, making them ideal for short-term insomnia treatment. Though they share some side effects with benzodiazepines, their shorter half-lives usually result in milder repercussions. However, their half-life can be extended in older patients, leading to side effects such as cognitive impairment and delirium, as well as central ataxia. On the other hand, ramelteon, a melatonin receptor agonist, stands out as a safe and effective option for the elderly.
Lesson Outline
Don't stop here!
Get access to 133 more Pharmacology lessons & 13 more medical school learning courses with one subscription!
FAQs
Nonbenzodiazepine hypnotics, such as zolpidem and zaleplon, modulate the GABA-A receptor by binding to its allosteric site. GABAA is a key inhibitory neurotransmitter in the CNS. By potentiating GABA-A transmission, these drugs promote sedation. Their primary therapeutic application is in the management of insomnia, particularly for difficulties with sleep initiation, owing to their swift onset of action.
In geriatric patients, nonbenzodiazepine hypnotics might heighten the risk of cognitive disturbances, delirium, and central ataxia. Notably, central ataxia can predispose the elderly to falls. Given these considerations, a cautious approach is essential when prescribing these drugs to older individuals, and concurrent use with other CNS depressants should be minimized.
Compared to benzodiazepines, nonbenzodiazepine hypnotics have a reduced propensity for the development of tolerance, withdrawal manifestations, and dependence. Flumazenil, a benzodiazepine receptor antagonist, can both counteract the sedative effects of nonbenzodiazepine hypnotics in case of overdose, though it can induce seizures.
Melatonin and its receptor agonist, ramelteon, play a vital role in managing insomnia by regulating the circadian rhythm. Their target receptors, MT1 and MT2, are strategically located within the suprachiasmatic nucleus of the hypothalamus, which orchestrates the body's sleep-wake cycle.
Ramelteon is typically well-received and considered safe for the geriatric population. With a relatively benign side effect profile, it often emerges as a drug of choice for older patients struggling with insomnia.
